P53 mutations in thyroid carcinoma: Tidings from an old foe

Journal of Endocrinological Investigation

Volumn 24, Issue 7, 2001, Pages 536-545

  Farid, N R ^a  

^a Osancor Biotech Inc   (United Kingdom)

Author keywords

CpG deamination; Differentiation; Epigenetic; Genomic instability; Mutations; p53; Radiation; Thyroid cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DINUCLEOTIDE; DNA; PROTEIN P53; TRANSCRIPTION FACTOR;

ANEUPLOIDY; APOPTOSIS; CANCER STATISTICS; CARCINOGENESIS; CELL CYCLE; CHROMOSOME ABERRATION; DATA BASE; DEAMINATION; DNA REPAIR; DRUG RESPONSE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MUTATION RATE; RADIATION EXPOSURE; REGULATORY MECHANISM; REVIEW; SILENT GENE; THYROID CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0034921646     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343889     Document Type: Review

References (59)

1. Surfing the p53 network
2. New approaches to understanding p53 gene tumor mutation spectra
3. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity
4. The ARF/p53 pathway
5. p53, the cellular gatekeeper for growth and cell division
6. The DNA damage response: Putting the check-points in perspective
7. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase
8. 14-3-3 Sigma is required to prevent mitotic catastrophe after DNA damage
9. Association of the cyclin-dependent kinases and the 14-3-3 sigma negatively regulates cell cycle progression
10. Apoptosis in cancer
11. De-mystifying the mechanism(s) of maspin
12. (WAF/CIPI), a cyclin-dependent protein kinase inhibitor in thyroid carcinomas
13. Expression of mdm-2 gene, a p53 binding protein in thyroid carcinogenesis
14. Pathogenesis of thyroid cancer: The significance of oncogenes, tumour suppressor genes and genomic instability
15. Thyroid carcinoma is characterized by genomic instability: Evidence from p53 mutations
16. Molecular basis of thyroid cancer
17. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas
18. Unique association of p53 mutations with undifferentiated carcinoma but not with differentiated tumors of the thyroid gland
19. Genetic alterations in thyroid tumor progression: Association with p53 gene mutations
20. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas
21. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland
22. p53 mutations in all stages of thyroid carcinoma
23. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinoma
24. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutations in two out of fifty-six thyroid tumours
25. Mutations in p53 tumour suppressor gene in thyroid tumours of children from areas contaminated by the Chernobyl accident
26. Alterations of p53 and expression of WAF/p21 in human thyroid tumors
27. Prevalence of mutations of ras and p53 in benign and malignant tumors from children exposed to radiation after the Chernobyl nuclear accident
28. p53 gene mutations in radiation-induced thyroid cancer
29. p53 gene mutations in thyroid carcinoma
30. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumors without radiation history
31. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggest involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma
32. s α, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in Korean population
33. Mutation of p53 in thyroid carcinoma with an insular component
34. Molecular alterations involving p53 codons 167 and 183 in papillary thyroid carcinoma from Chernobyl-contaminated regions of Belarus
35. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
36. How many mutations does it take to make a tumor?
37. Genetic instabilities in human cancers
38. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalysed by aneuploidy
39. Silent and multiple mutations in p53 and the question of the hypermutability of tumors
40. Geographic variation of p53 mutational profile in nonmalignant human liver
41. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells
42. Crystal structure of a p53 tumor-suppressor-DNA complex: Understanding tumorigenic mutations
43. Methylation of the oestrogen receptor CpG islands links ageing and neoplasis in human colon
44. Aging and DNA methylation in colorectal mucosa and cancer
45. Microsatellite instability: Marker of a mutated phenotype in cancer
46. Genetic reconstruction of individual colorectal tumor histories
47. p53 mutations in tumors derived from irradiated human thyroid epithelial cells
48. Mutagenesis by 8-oxoguanine: An enemy within
49. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: Oxyradical overload diseases
50. 131I) therapy
51. The risks and benefits of radioiodine therapy for thyroid carcinoma remain somewhat undifferentiated
52. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations
53. Hot-spot mutants of p53 core domain evince characteristic local structural changes
54. Pharmacological rescue of mutant p53 conformation and function
55. Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression
56. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathway
57. Regulation of the mdm2 oncogene by thyroid hormone receptor
58. Alteration of expression and impairment of function of the thyroid hormone receptor in human renal clear cell carcinoma (RCCC)